FiercePharma

Janssen's Invega Sustenna Will Become Decision Resources' Proprietary Clinical Gold Standard in 2013 for the Treatment of Schizo

A Drug's Impact on Global Symptoms and Its Effect on Positive Symptoms Are the Attributes that Most Influence Surveyed Psychiatrists' Prescribing Decisions in Schizophrenia, According to a New Report ...
FiercePharma

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

INVEGA SUSTENNA® (paliperidone palmitate) was approved by the U.S. FDA in July 2009 as the first once-monthly atypical long-acting injection to treat schizophrenia and is now approved in more than 80 ...
Medscape

FDA Approves Once-Monthly Paliperidone Palmitate Injection for Treating Schizophrenia

August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...
Business Insider

Invega Sustenna/Trinza (Paliperidone Palmitate; Johnson & Johnson) Drug Overview & Product Profiles 2018

The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering. Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are ...
Monthly Prescribing Reference

Invega Hafyera

Paliperidone (as palmitate) 1092mg/3.5mL, 1560mg/5mL; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...
The Motley Fool

Could This Game-Changing FDA Approval Mean Profit for Johnson & Johnson Shareholders?

Invega Hafyera is the third drug in Johnson & Johnson's Invega franchise to be approved, joining the monthly Invega Sustenna and quarterly Invega Trinza. Based on Invega Hafyera's similar efficacy to ...